Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Selected
COVID-19
Type of publications
Guidelines (1)
NITAG documentation (354)
SAGE documentation (33)
Scientific publications (4)
Systematic reviews (SYSVAC) (1089)
Regions
Africa (57)
Americas (187)
Eastern Mediterranean (10)
Europe (155)
South-East Asia (10)
Western Pacific (36)
Diseases
COVID-19 (1481)
Chikungunya (9)
Cholera (33)
Cytomegalovirus (1)
Dengue (39)
Diphtheria (79)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (66)
Hepatitis A (63)
Hepatitis B (153)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (66)
HIV / AIDS (10)
Human papillomavirus (HPV) (472)
Influenza (573)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (27)
Measles (128)
Meningococcal disease (145)
Mpox (55)
Mumps (46)
Pertussis (104)
Pneumococcal disease (266)
Poliomyelitis (84)
Q fever (1)
Rabies (28)
Rotavirus (115)
RSV (Respiratory syncytial virus) (47)
Rubella (64)
Salmonella (2)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (59)
Tick-borne encephalitis (12)
Tuberculosis (73)
Typhoid (23)
Varicella (69)
Yellow fever (42)
Zika (1)
Show more
Methodological quality (AMSTAR 2)
High (12)
Moderate (7)
Low (111)
Critically low (685)
Not applicable (274)
1481 results found
2020
∙
CAVEI
CAVEI provisional recommendation for the initial prioritization of groups to be vaccinated against SARS-CoV-2 in the context of limited supply
2020
∙
CAVEI
CAVEI recommendations to prioritize vaccination against SARS-COV-2 in health personnel during the campaign initiation phase and in the context of vaccine limited supply
2020
∙
Steve Anderson
CBER Plans for Monitoring COVID-19 Vaccine Safety and Effectiveness
2020
∙
Tom Shimabukuro, ACIP
CDC post-authorization/post-licensure safety monitoring of COVID-19 vaccines
2020
∙
Sara Oliver, ACIP
Clinical Considerations for Populations Included in Phase 1a
2020
∙
ACIP
Considerations for FDA Licensure vs. Emergency Use Authorization of COVID-19 Vaccines
2020
∙
Sara Oliver, ACIP
Considerations for Populations Included in Phase 1b and 1c
2020
COVID-19 vaccination: BioNTech/Pfizer
2020
∙
ACIP
COVID-19 vaccine implementation
2020
∙
Janell Routh, ACIP
COVID-19 Vaccine Implementation Planning Update
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register